Elda

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

This research aims to create a comprehensive database accessible to members of the AGAMENON - SEOM group for epidemiological and clinical research on esophageal and stomach cancer. The goal is to improve understanding of these cancers to optimize patient management, treatment, progression, and to compare data across different groups, enhancing scientific publications quality. The study is observational and collects data retrospectively from patient medical records. The study includes two groups of patients those with resectable non-advanced cancer and those with unresectable advanced cancer. Treatments recorded include surgery, chemotherapy, anti-targeted agents, immunotherapy, and radiotherapy. Data collection focuses on diagnostic and therapeutic approaches over a 12-month period. Participants information is gathered from medical records without active intervention. Researchers analyze diagnostic and treatment methods, epidemiological profiles, risk and prognostic factors, pathological features, and validate predictive models. The study spans up to 12 months for outcome measures, with participation involving no direct treatment or visits, only record review.

This research aims to collect detailed information about patients with lung cancer and other thoracic tumors to better understand the disease and treatment outcomes. It focuses on individualizing treatment based on markers that predict response to chemotherapy and molecular inhibitors. The study addresses challenges such as poor prognosis, variability in diagnosis and treatment, and the need for improved early detection and prevention strategies across Europe and Spain. The study is observational and multicenter, gathering data both retrospectively and prospectively from patients diagnosed and treated by medical professionals including thoracic surgeons and oncologists. It includes multiple groups of patients based on the type of thoracic tumor, such as non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic cancer, and carcinoid cancer. There are no experimental treatments instead, it involves comprehensive data collection on patient characteristics and treatments. Participants provide information from their medical history and treatment records over up to 10 years. Researchers study epidemiological and therapeutic factors related to thoracic tumors by reviewing clinical data. The main outcome is to describe characteristics of these tumors in Spanish patients. The study involves no interventions or medications, focusing on observation and data analysis to inform future care and research.